ES2536974T3 - Péptidos de epítopos del receptor de EGF y usos de los mismos - Google Patents

Péptidos de epítopos del receptor de EGF y usos de los mismos Download PDF

Info

Publication number
ES2536974T3
ES2536974T3 ES05723258.9T ES05723258T ES2536974T3 ES 2536974 T3 ES2536974 T3 ES 2536974T3 ES 05723258 T ES05723258 T ES 05723258T ES 2536974 T3 ES2536974 T3 ES 2536974T3
Authority
ES
Spain
Prior art keywords
egf receptor
epitope peptides
receptor epitope
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05723258.9T
Other languages
English (en)
Spanish (es)
Inventor
Terrance Grant Johns
Andrew Mark Scott
Antony Wilks Burgess
Lloyd J. Old
Timothy E. Adams
K. Dane Wittrup
Ginger Chao
Peter Anthony Hoyne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of ES2536974T3 publication Critical patent/ES2536974T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES05723258.9T 2004-02-20 2005-02-18 Péptidos de epítopos del receptor de EGF y usos de los mismos Active ES2536974T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54660204P 2004-02-20 2004-02-20
US546602P 2004-02-20
US58462304P 2004-07-01 2004-07-01
US584623P 2004-07-01
PCT/US2005/005155 WO2005081854A2 (fr) 2004-02-20 2005-02-18 Peptides d'epitopes du recepteur d'egf et ses applications

Publications (1)

Publication Number Publication Date
ES2536974T3 true ES2536974T3 (es) 2015-06-01

Family

ID=34915579

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05723258.9T Active ES2536974T3 (es) 2004-02-20 2005-02-18 Péptidos de epítopos del receptor de EGF y usos de los mismos

Country Status (8)

Country Link
US (2) US7767792B2 (fr)
EP (2) EP1722808B1 (fr)
JP (2) JP2008501308A (fr)
KR (2) KR101270443B1 (fr)
AU (2) AU2005216082B8 (fr)
CA (1) CA2556632C (fr)
ES (1) ES2536974T3 (fr)
WO (1) WO2005081854A2 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
ES2334494T5 (es) 2001-05-11 2013-05-29 Ludwig Institute For Cancer Research Ltd. Proteínas de unión específicas y usos de las mismas
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1578801A2 (fr) * 2002-12-27 2005-09-28 Domantis Limited Anticorps a domaine unique ayant une double specificite pour un ligand et son recepteur
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
US20070009972A1 (en) * 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
ZA200803759B (en) * 2005-11-02 2009-10-28 Univ Duke Concurrent chemotherapy and immunotherapy
BRPI0619225A2 (pt) * 2005-12-01 2017-11-07 Domantis Ltd monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória
EP2163563A1 (fr) * 2006-03-31 2010-03-17 Massachusetts Institute of Technology Traitement des tumeurs exprimant des récepteurs EGF mutants
WO2008033495A2 (fr) * 2006-09-15 2008-03-20 Life Science Pharmaceuticals Méthode de détection et de traitement de troubles cutanés
MX2009007987A (es) 2007-01-25 2010-03-01 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
AU2008218925A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
MX2009009782A (es) 2007-03-15 2010-09-10 Ludwig Inst Cancer Res Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
EP2147397A4 (fr) * 2007-04-23 2013-08-21 Univ Ramot Système, procédé, et support lisible par ordinateur pour fournir une image de sortie
UA102993C2 (ru) 2007-06-06 2013-09-10 Домантис Лимитед Анти-vegf единичный вариабельный домен иммуноглобулина
WO2009023266A1 (fr) * 2007-08-14 2009-02-19 Ludwig Institute For Cancer Research Production d'anticorps dirigés contre des récepteurs de surface cellulaire et des protéines associées au cancer comprenant des membres de la famille des récepteurs du facteur de croissance épidermique (egfr)
EP2188311B1 (fr) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Anticorps monoclonal 175 ciblant le récepteur egf et dérivées et utilisations de ceux-ci
EP2190861A4 (fr) 2007-08-22 2011-03-30 Univ California Polypeptides de liaison activables et procédés d'identification et utilisation de ceux-ci
EP2615115A3 (fr) 2007-11-30 2014-01-08 Glaxo Group Limited Produits de construction de liaison à un antigène
WO2009149094A2 (fr) * 2008-06-02 2009-12-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide egfr défini par lymphocyte t cytotoxique et peptide dérivé optimisé
JP2010006705A (ja) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Ｈｅｒ２サブセット
JP2011525241A (ja) * 2008-06-18 2011-09-15 アボット・ラボラトリーズ ＰｌＧＦ−１コンパニオン診断方法および製品
US20100004306A1 (en) * 2008-06-18 2010-01-07 Abbott Laboratories PIGF-1 Assay and kits and components thereof
US8741287B2 (en) * 2008-06-18 2014-06-03 Abbott Laboratories PlGF-1 assay and kits and components thereof
WO2010077643A1 (fr) * 2008-12-08 2010-07-08 Tegopharm Corporation Ligands de masquage pour inhibition réversible de composés polyvalents
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
JP5851842B2 (ja) 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
WO2010096838A2 (fr) * 2009-02-23 2010-08-26 Cytomx Therapeutics, Llc Proprotéines et leurs procédés d'utilisation
KR101477762B1 (ko) * 2009-09-22 2014-12-30 상하이 캔서 인스티튜트 특이성 결합 단백질 및 용도
CN102127147B (zh) * 2010-01-20 2014-07-02 上海市肿瘤研究所 表皮生长因子受体模拟表位肽及其应用
CN103539840B (zh) * 2010-01-20 2015-04-01 上海市肿瘤研究所 表皮生长因子受体模拟表位肽及其应用
JP2013534515A (ja) 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
WO2012024659A2 (fr) 2010-08-20 2012-02-23 Massachusetts Institute Of Technology Constructions à base d'anticorps dirigées contre des récepteurs de tyrosine kinase
EP2699268A2 (fr) 2011-04-21 2014-02-26 Seattle Genetics, Inc. Nouveaux conjugués liant-principe actif (adc) et leur utilisation
IN2014DN08778A (fr) * 2012-03-27 2015-05-22 Green Cross Corp
JP6103832B2 (ja) 2012-06-25 2017-03-29 Hoya株式会社 Ｅｇｆｒ結合性ペプチド
CN106163568B (zh) 2013-12-23 2021-03-23 拜耳制药股份公司 含纺锤体驱动蛋白（ksp）的抗体药物偶联物（adc）
EP3126388B1 (fr) 2014-03-11 2019-05-08 Regeneron Pharmaceuticals, Inc. Anticorps anti-egfrviii et utilisations associées
EP4218929A1 (fr) 2014-03-21 2023-08-02 AbbVie Inc. Anticorps anti-egfr et conjugués anticorps-médicament
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
CN108513593A (zh) 2015-04-23 2018-09-07 南托米克斯有限责任公司 癌症新表位
CN108025084A (zh) 2015-06-22 2018-05-11 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
WO2017060322A2 (fr) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Conjugué anticorps-médicament (adc) inhibiteur de ptefb
EP3362930A4 (fr) 2015-10-12 2019-06-19 Nantomics, LLC Systèmes, compositions, et procédés de découverte de msi et de néoépitopes qui prévoient la sensibilité à des points de contrôle immunitaires
SG10202008909VA (en) 2016-03-24 2020-10-29 Bayer Pharma AG Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CN109310781B (zh) 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
WO2018114804A1 (fr) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Conjugués anticorps-principe actif (adc) spécifiques renfermant des inhibiteurs de ksp
WO2018114798A1 (fr) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Promédicaments de principes actifs cytotoxiques contenant des groupes divisibles par voie enzymatique
IL310558A (en) 2016-12-21 2024-03-01 Bayer Pharma AG Drug-antibody conjugates with enzymatically cleavable groups
MA55089A (fr) 2019-02-26 2022-01-05 Janssen Biotech Inc Traitements combinés et stratification des patients avec des anticorps bispécifiques anti-egfr/c-met
AU2020247828A1 (en) * 2019-03-22 2021-11-18 Certis Therapeutics Pty Ltd Anti-HER2 binding molecules
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
CN111647074B (zh) * 2020-06-01 2023-12-19 皖南医学院 一种her3二聚化界面抗原肽、重组抗原肽、编码基因及其应用
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
AU2022298653A1 (en) 2021-06-22 2023-10-12 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibody drug conjugates and uses thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE31006E (en) 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4451570A (en) 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU633867B2 (en) 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
JP2975679B2 (ja) 1989-09-08 1999-11-10 ザ・ジョーンズ・ホプキンス・ユニバーシティ ヒト神経膠腫のｅｇｆ受容体遺伝子の構造変化
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5459061A (en) 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
WO1991016350A1 (fr) 1990-04-20 1991-10-31 Ludwig Institute For Cancer Research Formes de proteines, d'arn et d'adn du recepteur de facteurs de croissance epidermique, et procede
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
AU649275B2 (en) 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1994001137A1 (fr) 1992-07-06 1994-01-20 Hybritech Incorporated Procede d'aministration d'agents cytotoxiques et constituants de ceux-ci
CA2150262C (fr) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Proteines fixatrices multivalentes et multispecifiques, fabrication et utilisation
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
CA2206343C (fr) 1994-11-28 2009-04-07 Thomas Jefferson University Reactifs et procede de ciblage des recepteurs mutants du facteur de croissance de l'epiderme
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5708156A (en) 1996-05-31 1998-01-13 Ilekis; John V. Epidermal growth factor receptor-like gene product and its uses
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5942602A (en) 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
NZ518477A (en) * 1999-10-29 2004-10-29 Genentech Inc Isolated anti-prostate stem cell antigen (PSCA) antibodies that internalise upon binding to PSCA on a mammalian cell, including a PSCA-expressing tumour cell, in vivo
JP2003523207A (ja) * 2000-01-25 2003-08-05 ジェネンテック・インコーポレーテッド Ｌｉｖ−１関連タンパク質、それをコードするポリヌクレオチド、及び癌の治療へのその利用
AU2001295002B2 (en) 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
ES2334494T5 (es) 2001-05-11 2013-05-29 Ludwig Institute For Cancer Research Ltd. Proteínas de unión específicas y usos de las mismas
NZ530212A (en) * 2001-06-13 2006-09-29 Genmab As An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR)
US20040248196A1 (en) * 2001-08-03 2004-12-09 Adams Timothy Edward Methods of screening based on the egf receptor crystal structure
AU2003236346A1 (en) * 2002-04-11 2003-10-20 Fuso Pharmaceutical Industries, Ltd. Monoclonal antibody neutralizing megsin
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
WO2005118876A2 (fr) 2004-06-04 2005-12-15 Genentech, Inc. Mutations de egfr
MX2007006529A (es) 2004-12-07 2007-06-22 Genentech Inc Seleccionar pacientes para terapia con un inhibidor her.
WO2008033495A2 (fr) 2006-09-15 2008-03-20 Life Science Pharmaceuticals Méthode de détection et de traitement de troubles cutanés
MX2009007987A (es) 2007-01-25 2010-03-01 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
MX2009009782A (es) 2007-03-15 2010-09-10 Ludwig Inst Cancer Res Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
EP2188311B1 (fr) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Anticorps monoclonal 175 ciblant le récepteur egf et dérivées et utilisations de ceux-ci
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
KR20070031871A (ko) 2007-03-20
CA2556632C (fr) 2016-10-11
KR20120050530A (ko) 2012-05-18
KR101280267B1 (ko) 2013-07-15
WO2005081854A3 (fr) 2006-01-05
JP2012102109A (ja) 2012-05-31
AU2005216082B2 (en) 2010-10-14
WO2005081854A2 (fr) 2005-09-09
JP2008501308A (ja) 2008-01-24
EP1722808A2 (fr) 2006-11-22
JP6045147B2 (ja) 2016-12-14
EP1722808A4 (fr) 2009-08-19
KR101270443B1 (ko) 2013-05-31
AU2010224335A1 (en) 2010-10-14
EP2514763A1 (fr) 2012-10-24
AU2005216082A1 (en) 2005-09-09
US7767792B2 (en) 2010-08-03
AU2010224335B2 (en) 2012-04-05
AU2005216082B8 (en) 2010-11-18
EP1722808B1 (fr) 2015-04-08
US20100322937A1 (en) 2010-12-23
US20050255555A1 (en) 2005-11-17
CA2556632A1 (fr) 2005-09-09
US8652473B2 (en) 2014-02-18

Similar Documents

Publication Publication Date Title
ES2536974T3 (es) Péptidos de epítopos del receptor de EGF y usos de los mismos
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
CO5700788A2 (es) Composiciones y metodos para inmunoterapia especifica de wt1
ES2528133T3 (es) Péptidos y composiciones para prevención de la adhesión celular, y métodos para utilizar los mismos
ES2507094T3 (es) Proteína específica del timo
PE20120792A1 (es) Variantes de peptidos natriureticos de tipo c
PE20090711A1 (es) Region constante de anticuerpo mutante
AR072009A1 (es) Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos
HRP20090245T1 (en) Pyy agonists and uses thereof
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
AR078374A1 (es) Peptidos aislados de veneno de arana y sus usos como potentes y selectivos bloqueadores del canal ionico
PE20130615A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
AR050353A1 (es) Composicion de anticuerpo her2
ES2723774T3 (es) Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
AR049014A1 (es) Mimeticuerpos de glp-1 humanos , composiciones y usos
PA8559801A1 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus de tipo ii
CO6351811A2 (es) La proteina de tuberculosis rv2386c, composiciones y usos de la misma
RS53872B1 (en) NEW AND POWERFUL CLASS II MHC PEPTIDES DERIVATED FROM SURVIVINE AND UNAURANTS
NO20063026L (no) Antistoffer
CO5700785A2 (es) Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal
ES2619332T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
AR077879A1 (es) Inmunoconjugados dirigidos
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
CO6251278A2 (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol